SubsidieMeestersChemometric histopathology via coherent Raman imaging for precision medicine
The CHARM project aims to revolutionize cancer diagnosis with a novel AI-integrated, label-free tissue analysis system, achieving high accuracy in tumor identification and classification.
Projectdetails
Introduction
The CHARM project aims to radically transform the cancer diagnosing process and bring the emerging field of digital histopathology to the next level. It introduces a novel technology for tissue analysis, capable of measuring the molecular composition of patient tissue samples and recognizing and classifying tumors in a completely label/stain-free way.
Technology Overview
The instrument, integrated with artificial intelligence (AI), will offer histopathologists a reliable, fast, and low-cost Clinical Decision Support System (CDSS) for cancer diagnosis and personalized cancer therapy.
- We will develop a Class C medical device (IVDR, In-Vitro Diagnostic Regulation).
- This device will consist of a turnkey low-cost broadband Coherent Raman Scattering (CRS) microscope.
- The microscope will be enabled by our patented graphene-based fiber laser technology and will be named the Chemometric Pathology System (CPS).
- The CPS will integrate an AI module based on deep learning, statistics, and machine learning.
Capabilities of the CPS
The CPS will be capable of automatically analyzing unstained tissues, providing:
- Fast and accurate tumor identification (differentiating normal vs neoplastic tissues) with accuracy >98%.
- Final tumor diagnosis prediction (differentiating and grading histologic subtypes) with accuracy >90%.
This will offer histopathologists a decision tree compatible with existing clinical protocols but with biomolecular-based objectivity and reduced time to result (TRL6).
Business Development
We will develop a robust business case for the application and ensure the project's continuation to higher TRLs and the final market entrance.
Previous Work
This proposal builds on the results of the ERC POC project GSYNCOR.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.441.979 |
| Totale projectbegroting | € 2.441.979 |
Tijdlijn
| Startdatum | 1-5-2022 |
| Einddatum | 31-10-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- CAMBRIDGE RAMAN IMAGING SRLpenvoerder
- POLITECNICO DI MILANO
- UNIVERSITATSKLINIKUM JENA
- INSPIRALIA SOCIEDAD LIMITADA
- IN SRL IMPRESA SOCIALE
- CONSIGLIO NAZIONALE DELLE RICERCHE
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Deep Label-Free Cell Imaging of Liquid Biopsies for Cancer MonitoringDevelop and commercialize a label-free interferometric phase microscopy device with AI for cost-effective cancer diagnosis and monitoring via liquid biopsies. | ERC POC | € 150.000 | 2023 | Details |
Backscattering coherent Stokes Raman scattering (sCiSsoRS) for real-time cancer diagnosticsThis project aims to enhance real-time cancer diagnosis during surgery by developing backward Coherent Stokes Raman Scattering (CSRS) for rapid, HE-like imaging of thick tissue samples. | ERC COG | € 2.432.705 | 2024 | Details |
Fast and simple biomarker detection by computational microscopyWe developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics. | ERC POC | € 150.000 | 2024 | Details |
ADAPTIVE OPTICAL METASURFACES FOR REAL-TIME, LABEL-FREE AND NON-DESTRUCTIVE 7D DIGITAL PATHOLOGYOPTIPATH aims to revolutionize tissue diagnosis by providing real-time, non-destructive 3D imaging using advanced optical technologies and machine learning to enhance accuracy and reduce variability. | EIC Pathfinder | € 3.276.577 | 2025 | Details |
Deep Label-Free Cell Imaging of Liquid Biopsies for Cancer Monitoring
Develop and commercialize a label-free interferometric phase microscopy device with AI for cost-effective cancer diagnosis and monitoring via liquid biopsies.
Backscattering coherent Stokes Raman scattering (sCiSsoRS) for real-time cancer diagnostics
This project aims to enhance real-time cancer diagnosis during surgery by developing backward Coherent Stokes Raman Scattering (CSRS) for rapid, HE-like imaging of thick tissue samples.
Fast and simple biomarker detection by computational microscopy
We developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics.
ADAPTIVE OPTICAL METASURFACES FOR REAL-TIME, LABEL-FREE AND NON-DESTRUCTIVE 7D DIGITAL PATHOLOGY
OPTIPATH aims to revolutionize tissue diagnosis by providing real-time, non-destructive 3D imaging using advanced optical technologies and machine learning to enhance accuracy and reduce variability.